Outcomes of Patients With High-Risk Plaques Treated With a Bioresorbable Magnesium Scaffold: Insights From the BIOMAG-I Study
A dissolving heart stent performed well in patients with dangerous coronary plaques, offering a potentially safer intervention for vulnerable atherosclerosis.
This BIOMAG-I post-hoc analysis shows favorable in-vivo performance of the third-generation bioresorbable magnesium scaffold in high-risk coronary plaques, with low late lumen loss across all subgroups including thin-cap fibrous atheromas. The results position DREAMS 3G as a promising intervention for vulnerable plaques, though confirmation in larger prospective studies is warranted.
What the study was
- Study design
- Post-hoc analysis of a prospective single-arm trial (BIOMAG-I, first-in-human DREAMS 3G scaffold)
- Population
- Patients with stable CAD and high-quality intravascular imaging from BIOMAG-I trial (50.6% had high-risk plaque features by μFR+PB criteria); international multicenter
- Sample size
- 83
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Catheterization and Cardiovascular Interventions
Why it surfaced
Interesting cardiovascular device data with novel 'leave-nothing-behind' concept for vulnerable plaques. Post-hoc design and small n=83 limit score. Not primary cardiometabolic drug/metabolic focus of watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.